Characteristics of Guillain-Barre Syndrome Patient Underwent Hyperbaric Oxygen Therapy at Lakesla 2016–2019

Ni Komang Sri Dewi Untari; Kurnia  Kusumastuti; Guritno Suryokusumo; I Ketut Sudiana

doi:10.3889/oamjms.2021.6679

Authors

Ni Komang Sri Dewi Untari Department of Hyperbaric, Drs. Med. Rijadi S. Phys. Naval Health Institute, Surabaya, Indonesia; Department of Neurology, Faculty of Medicine, Hang Tuah University, Dr. Ramelan Navy Hospital, Surabaya, Indonesia; Outside Lecturer, Hyperbaric Medicine, Basic Medical Science, Master Program, Airlangga University, Surabaya, Indonesia
Kurnia Kusumastuti Department of Neurology, Faculty of Medicine, Airlangga University, Surabaya, Indonesia
Guritno Suryokusumo Department of Hyperbaric, Faculty of Medicine, Pembangunan Nasional University, Jakarta, Indonesia
I Ketut Sudiana Department of Pathology Anatomy, Faculty of Medicine, Airlangga University, Surabaya, Indonesia

DOI:

https://doi.org/10.3889/oamjms.2021.6679

Keywords:

Characteristics, Guillain-Barre syndrome, Hyperbaric oxygen therapy

Abstract

BACKGROUND: Guillain-Barre syndrome (GBS) is considered an acute immune-mediated monophasic illness. Standard therapy includes intravenous immunoglobulin (IVIG) and/or plasmapheresis. Yet, long-standing disability remains a problem. In Indonesia, the availability and cost of these therapies are constraints.

AIM: To show the capability of hyperbaric oxygen (HBO2) therapy in GBS patients who did not undergo standard therapy. HBO2 also provides healing in patients who experience delays in therapy.

METHODS: Data included identity, demographic, social history, current disease history, disease progression and therapies used. Data were displayed in the form of tables and graphs.

RESULTS: Twenty-five GBS patients underwent HBO2 from 2016 to 2019. The majority of patients were males aged 20-30 years, triggered by preceding diarrhea. After approximately three to ten days following HBO2, they felt their first positive changes. They walked with assistance after two to three weeks receiving HBO2 and without assistance after four to 12 weeks receiving HBO2.

CONCLUSION: HBO2 administration show clinical improvement in GBS patients. HBO2 is expected to become an adjuctive therapy for GBS patients in Indonesia.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Head VA, Wakerley BR. Guillain-Barré syndrome in general practice: Clinical features suggestive of early diagnosis. Br J Gen Pract. 2016;66(645):218-9. https://doi.org/10.3399/bjgp16X684733 PMid:27033501 DOI: https://doi.org/10.3399/bjgp16X684733

St Charles JL, Bell JA, Gadsden BJ, Malik A, Cooke H, van de Grift LK, et al. Guillain Barré syndrome is induced in non-obese diabetic (NOD) mice following campylobacter jejuni infection and is exacerbated by antibiotics. J Autoimmun. 2017;77:11-38. https://doi.org/10.1016/j.jaut.2016.09.003 PMid:27939129 DOI: https://doi.org/10.1016/j.jaut.2016.09.003

Yuki N, Hartung H. Guillain-Barré syndrome. N Engl J Med. 2012;366(23):2294-304. https://doi.org/10.1056/NEJMra1114525 PMid:22694000 DOI: https://doi.org/10.1056/NEJMra1114525

Dimachkie MM, Barohn RJ. Guillain-Barré syndrome and variants. Neurol Clin. 2013;31(2):491-510. https://doi.org/10.1016/j.ncl.2013.01.005 Mid:23642721 DOI: https://doi.org/10.1016/j.ncl.2013.01.005

Wakerley BR, Yuki N. Infectious and noninfectious triggers in Guillain-Barré syndrome. Expert Rev Clin Immunol. 2013;9(7):627-39. https://doi.org/10.1586/17446 66X.2013.811119 Mid:23899233 DOI: https://doi.org/10.1586/1744666X.2013.811119

Poropatich KO, Walker CLF, Black RE. Quantifying the association between campylobacter infection and Guillain- Barre syndrome: A systematic review. J Health Popul Nutr. 2010;28(6):545-52. PMid:21261199 DOI: https://doi.org/10.3329/jhpn.v28i6.6602

Tam CC, O’Brien SJ, Rodrigues LC. Influenza, campylobacter and Mycoplasma infections, and hospital admissions for Guillain-Barré syndrome, England. Emerg Infect Dis. 2006;12(12):1880-7. https://doi.org/10.3201/eid1212.051032 PMid:17326939 DOI: https://doi.org/10.3201/eid1212.051032

Vucic S, Kieman MC, Cornblath DR. Guillain-Barré syndrome: An update. J Clin Neurosci. 2009;16(6):733-41. https://doi.org/10.1016/j.jocn.2008.08.033 PMid:19356935 DOI: https://doi.org/10.1016/j.jocn.2008.08.033

Nafissi S, Vahabi Z, Ghahar MS, Amirzargar AA, Naderi S. The role of cytomegalovirus, haemophilus influenzae and epstein barr virus in Guillain Barre syndrome. Acta Med Iran. 2013;51(6):372-6. PMid:23852841

Dahbour SS. Clinical experience with Gullain Barre syndrome over a 6-year period in one hospital in the Middle East. Jordan Med J. 2009;43(4):280-5.

Barbi L, Coelho AV, de Alencar LC, Crovella S. Prevalence of Guillain-Barré syndrome among Zika virus infected cases: A systematic review and meta-analysis. Braz J Infect Dis. 2018;22(2):137-41. https://doi.org/10.1016/j.bjid.2018.02.005 PMid:29545017 DOI: https://doi.org/10.1016/j.bjid.2018.02.005

Cao-Lormeau VM, Blake A, Mons S, Lastère S, Roche C, Vanhomwegen J, et al. Guillain-Barré syndrome outbreak associated with Zika virus infection in French Polynesia: A case-control study. Lancet. 2016;387(10027):1531-9. https://doi.org/10.1016/S0140-6736(16)00562-6 PMid:26948433 DOI: https://doi.org/10.1016/S0140-6736(16)00562-6

Méndez N, Oviedo-Pastrana M, Mattar S, Caicedo-Castro I, Arrieta G. Zika virus disease, microcephaly and Guillain- Barré syndrome in Colombia: Epidemiological situation during 21 months of the Zika virus outbreak, 2015-2017. Arch Public Health. 2017;75(1):65. https://doi.org/10.1186/s13690-017-0233-5 PMid:29118981 DOI: https://doi.org/10.1186/s13690-017-0233-5

Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barré syndrome: A systematic review and meta-analysis. Neuroepidemiology. 2011;36(2):123-33. https://doi.org/10.1159/000324710 PMid:21422765 DOI: https://doi.org/10.1159/000324710

Webb AJS, Brain SAE, Wood R, Rinaldi S, Turner MR. Seasonal variation in Guillain-Barré syndrome: A systematic review, meta-analysis and Oxfordshire cohort study. J Neurol Neurosurg Psychiatry. 2015;86(11):1196-201. https://doi.org/10.1136/jnnp-2014-309056 PMid:25540247 DOI: https://doi.org/10.1136/jnnp-2014-309056

Candra E. GBS Patients Increase in Productive Age; 2012.

Zhang Y, Zhao Y, Wang Y. Prognostic factors of Guillain-Barré syndrome: A 111-case retrospective review. Chin Neurosurg J. 2018;4(1):1-9. https://doi.org/10.1186/s41016-018-0122-y DOI: https://doi.org/10.1186/s41016-018-0122-y

González-Suárez I, Sanz-Gallego I, Rodríguez de Rivera FJ, Arpa J. Guillain-Barré syndrome: Natural history and prognostic factors: A retrospective review of 106 cases. BMC Neurol. 2013;13:95. https://doi.org/10.1186/1471-2377-13-95 PMid:23876199 DOI: https://doi.org/10.1186/1471-2377-13-95

Patwa HS, Chaudhry V, Katzberg H, Rae-Grant AD, So YT. Evidence-based guideline: Intravenous immunoglobulin in the treatment of neuromuscular disorders: Report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology. 2012;78(13):1009-15. https://doi.org/10.1212/WNL.0b013e31824de293 PMid:22454268 DOI: https://doi.org/10.1212/WNL.0b013e31824de293

Lünemann JD, Nimmerjahn F, Dalakas MC. Intravenous immunoglobulin in neurology-mode of action and clinical efficacy. Nat Rev Neurol. 2015;11(2):80-9. https://doi.org/10.1038/nrneurol.2014.253 PMid:25561275 DOI: https://doi.org/10.1038/nrneurol.2014.253

van den Berg B, Bunschoten C, van Doorn PA, Jacobs BC. Mortality in Guillain-Barré syndrome. Neurology. 2013;80(18):1650-4. https://doi.org/10.1212/WNL.0b013e3182904fcc Mid:23576619 DOI: https://doi.org/10.1212/WNL.0b013e3182904fcc

Ng KK, Howard RS, Fish DR, Hirsch NP, Wiles CM, Murray NM, et al. Management and outcome of severe Guillain-Barré syndrome. QJM. 1995;88(4):243-50. https://doi.org/10.1093/oxfordjournals.qjmed.a069055 PMid:7796073 DOI: https://doi.org/10.1093/oxfordjournals.qjmed.a069055

Yan L, Liang T, Cheng O. Hyperbaric oxygen therapy in China. Med Gas Res. 2015;5(1):3. https://doi.org/10.1186/s13618-015-0024-4 PMid:25722849 DOI: https://doi.org/10.1186/s13618-015-0024-4

World Health Organization. ICD-10 Online Versions. Geneva: World Health Organization; 2016.

van Doorn PA. Diagnosis, treatment and prognosis of Guillain- Barré syndrome (GBS). Presse Med. 2013;42(6):e193-201. https://doi.org/10.1016/j.lpm.2013.02.328 PMid:23628447 DOI: https://doi.org/10.1016/j.lpm.2013.02.328

Notturno F, Kokubun N, Sekiguki Y, Nagashima T, de Lauretis A, Yuki N, et al. Demyelinating Guillain-Barré syndrome recurs more frequently than axonal subtypes. J Neurol Sci. 2016;365:132-6. https://doi.org/10.1016/j.jns.2016.02.053 PMid:27206890 DOI: https://doi.org/10.1016/j.jns.2016.02.053

Burns TM. Guillain-Barré syndrome. Semin Neurol. 2008;28(2):152-67. https://doi.org/10.1055/s-2008-1062261 PMid:18351518 DOI: https://doi.org/10.1055/s-2008-1062261

Abai S, Kim SB, Kim JP, Lim YJ. Guillain-Barré syndrome combined with acute cervical myelopathy. J Korean Neurosurg Soc. 2010;48(3):298-300. https://doi.org/10.3340/jkns.2010.48.3.298 PMid:21082065 DOI: https://doi.org/10.3340/jkns.2010.48.3.298

Walling AD, Dickson G. Guillain-Barré syndrome. Am Fam Physician. 2013;87(3):192-7. PMid:23418763

Liska GM, Lippert T, Russo E, Nieves N, Borlongan CV. A dual role for hyperbaric oxygen in stroke neuroprotection: Preconditioning of the brain and stem cells. Cond Med. 2018;1(4):151-66. PMid:30079404

Tandel H, Vanza J, Pandya N, Jani P. Guillain-Barré syndrome (GBS): A review. Eur J Pharm Med Res. 2016;3(2):366-71.

Feasby TE, Hahn AF, Brown WF, Bolton CF, Gilbert JJ, Koopman WJ. Severe axonal degeneration in acute Guillain-Barré syndrome: Evidence of two different mechanisms? J Neurol Sci. 1993;116(2):185-92. https://doi.org/10.1016/0022-510X(93)90324-R PMid:8336165 DOI: https://doi.org/10.1016/0022-510X(93)90324-R

Asiri S, Altwaijri WA, Ba-Armah D, Al Rumayyan A, Alrifai MT, Salam M, et al. Prevalence and outcomes of Guillain-Barré syndrome among pediatrics in Saudi Arabia: A 10-year retrospective study. Neuropsychiatr Dis Treat. 2019;15:627-35. DOI: https://doi.org/10.2147/NDT.S187994

Harms M. Inpatient management of Guillain-Barré syndrome. Neurohospitalist. 2011;1(2):78-84. https://doi.org/10.1177/1941875210396379 PMid:23983841 DOI: https://doi.org/10.1177/1941875210396379

Kleyweg RP, van der Meche FGA. Treatment related fluctuations in Guillain-Barre syndrome after high-dose immunoglobulins or plasma-exchange. J Neurol Neurosurg Psychiatry. 1991;54(11):957-60. https://doi.org/10.1136/jnnp.54.11.957 PMid:1800666 DOI: https://doi.org/10.1136/jnnp.54.11.957

Ramakrishnan S, Mustare V, Philip M, Thennarasu K, Periyavan S. Treatment-related fluctuations in guillain barre syndrome and the conundrum of additional cycles of plasmapheresis. Ann Indian Acad Neurol. 2017;20(4):372-7. https://doi.org/10.4103/aian.AIAN_242_17 PMid:29184340 DOI: https://doi.org/10.4103/aian.AIAN_242_17

Zhai WW, Sun L, Yu ZQ, Chen G. Hyperbaric oxygen therapy in experimental and clinical stroke. Med Gas Res. 2016;6(2):111-8. https://doi.org/10.4103/2045-9912.184721 Mid:27867477 DOI: https://doi.org/10.4103/2045-9912.184721

Bennett MH, Weibel S, Wasiak J, Schnabel A, French C, Kranke P. Hyperbaric oxygen therapy for acute ischaemic stroke. Stroke. 2015;46(5):e109-10. https://doi.org/10.1002/14651858.CD004954.pub3 DOI: https://doi.org/10.1161/STROKEAHA.115.008296